Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3385-3390

  Cantarella, Giuseppina ^a   Liniger, Matthias ^b   Zuniga, Armando ^b   Schiller, John T ^c   Billeter, Martin ^d   Naim, Hussein Y ^b   Glueck, Reinhard ^a,b  

^a Etna Biotech srl   (Italy)

^b CRUCELL HOLLAND BV   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

HPV L1; Recombinant MV; Reverse genetics

Indexed keywords

CAPSID PROTEIN L1; MEASLES VIRUS VECTOR; MEMBRANE COFACTOR PROTEIN; MORATEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CELL CULTURE; CONTROLLED STUDY; GENE TRANSFER; GENETIC STABILITY; HELPER CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOSTIMULATION; MEASLES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; UTERINE CERVIX CARCINOMA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ATTENUATION; VIRUS GENE; VIRUS REPLICATION; WART VIRUS;

ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MEASLES VIRUS; MICE; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; RECOMBINANT PROTEINS; UTERINE CERVICAL NEOPLASMS; VACCINES, SYNTHETIC; VERO CELLS; VIRUS REPLICATION;

EID: 67349241388     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.061     Document Type: Article

References (23)

1. Howley P.H., and Lowy D.R. Papillomaviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. Fifth edition vol. 2 (2007), Lippincott Williams, Wilkins, Philadelphia 2299-2354
2. Gissmann L., and zur Hausen H. Human papilloma viruses: physical mapping and genetic heterogeneity. Proc Natl Acad Sci USA 73 (1976) 1310-1313
3. Muñoz N., Bosch F.X., Castellsagué X., Díaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
4. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999) 12-19
5. Molijn A., Kleter B., Quint W., and van Doorn L.-J. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 32 1 (2005) S43-S51
6. Winters U., Roden R., Kitchener H., and Stern P. Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag 2 3 (2006) 259-269
7. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89 (1992) 12180-12184
8. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92 (1995) 11553-11557
9. Schiller J.T., and Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2 4 (2004) 343-347
10. Das B.C., Hussain S., Nasare V., and Bharadwaj M. Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 26 (2008) 2669-2679
11. Griffin D.E. Measles virus. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. Fifth edition vol. 2 (2007), Lippincott Williams, Wilkins, Philadelphia 1551-1585
12. Radecke F., Spielhofer P., Schneider H., Kaelin K., Huber M., and Billeter M.A. Rescue of measles viruses from cloned DNA. EMBO J 14 (1995) 5773-5784
13. Singh M., Cattaneo R., and Billeter M.A. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 73 6 (1999) 4823-4828
14. Singh M., and Billeter M.A. A recombinant measles virus expressing biologically active human interleukin-12. J Gen Virol 80 (1999) 101-106
15. Zuniga A., Wang Z., Liniger M., Hangartner L., Billeter M.A., Naim H.Y., et al. Attenuated measles virus as a vaccine vector. Vaccine 25 (2007) 2974-2983
16. Tangy F., and Naim H.Y. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 18 (2005) 317-326
17. Liniger M., Zuniga A., Tamin A., Azzouz-Morin T.N., Knuchel M., Rota P.A., et al. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 26 (2008) 2164-2174
18. Mrkic B., Pavlovic J., Rulicke T., Atkinson J.P., Aguzzi A., Cattaneo R., et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol 72 (1998) 7420-7427
19. Wang Z., Hangartner L., Cornu T.I., Zuniga A., Billeter M.A., Naim H.Y., et al. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 19 (2001) 2329-2336
20. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual. 2nd edn. (1989), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
21. Billeter MA, Naim HY, Udem SA. Reverse genetics of measles virus and resulting multivalent recombinant vaccines. In: Griffin DE, Oldstone MBA, editors. Measles-history and basic biology. Curr Top Microbiol Immunol. Berlin, Heidelberg: Springer-Verlag; in press [chapter 7].
22. Dörig R.E., Marcil A., Chopra A., and Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75 2 (1993) 295-305
23. Naniche D., Varior-Krishnan G., Wild T.F., Rossi B., Rabourdin-Combe C., Gerlier D., et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67 10 (1993) 6025-6032